Behbahani Ali: insider trades.
Behbahani Ali reported 8 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 1 sale ($781K), across 3 companies.
- Transactions
- 8
- Purchases (P)
- 0
- Sales (S)
- 1
- Companies
- 3
- Name as filed
- Behbahani Ali
Companies
| Company | Relationship | Transactions |
|---|---|---|
| CRISPR Therapeutics AG (CRSP) | Director | 4 |
| Monte Rosa Therapeutics, Inc. (GLUE) | Director | 3 |
| Black Diamond Therapeutics, Inc. | Director | 1 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-18 | Black Diamond Therapeutics, Inc. | A | 7,707 | $1.93 | 110,236 | Form 4 |
| 2026-09-17 | CRISPR Therapeutics AG | S | 13,679 | $57.09 | 16,637 | Form 4 |
| 2026-09-17 | CRISPR Therapeutics AG | M | 30,000 | $14 | 30,316 | Form 4 |
| 2026-07-01 | Monte Rosa Therapeutics, Inc. | J | 15,000 | $0 | 0 | Form 4 |
| 2026-07-01 | Monte Rosa Therapeutics, Inc. | J | 15,000 | $0 | 15,000 | Form 4 |
| 2026-07-01 | Monte Rosa Therapeutics, Inc. | J | 1,000,000 | $0 | 6,692,298 | Form 4 |
| 2025-08-06 | CRISPR Therapeutics AG | J | 60 | $0 | 316 | Form 4 |
| 2025-08-06 | CRISPR Therapeutics AG | J | 15 | $0 | 29 | Form 4 |
Questions
What stock did Behbahani Ali buy or sell?
Behbahani Ali reported 8 non-derivative transactions on 4 SEC ownership filings in Q3 2026: 0 open-market purchases and 1 sale ($781K), across 3 companies.
Is Behbahani Ali the same person as other filers with this name?
This page covers SEC CIK 1613867 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/behbahani-ali-1613867.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.